Gland Pharma Limited
All news and filings related to Gland Pharma Limited.
View all news & filings- Medium impact
Gland Pharma to Acquire 100% of Gland US by Oct 31, 2026
Gland Pharma Limited will acquire 100% of Gland Pharma USA Inc. by October 31, 2026. The cash consideration is USD 5,01,208. This acquisition aims to streamline the corporate structure and remove layers. Gland US markets and distributes pharmaceutical products in the USA.
Read the summary - Medium impact
Gland Pharma Acquires 100% of Gland US for $501,208 to Streamline Corporate Structure
Gland Pharma Limited will acquire 100% of Gland Pharma USA Inc. for USD 5,01,208 to streamline its corporate structure. The acquisition is expected to be completed by October 31, 2026. Gland US is involved in pharmaceutical marketing and distribution in the USA.
Read the summary - Low impact
Gland Pharma Allots 44,193 Shares on ESOP Exercise; Closes 2019 Scheme
Gland Pharma allotted 44,193 equity shares to 36 employees upon exercise of stock options under ESOP 2025 and ESOP 2019. The company also closed its ESOP 2019 scheme. The total issued share capital increased to ₹16.50 crore.
Read the summary - Low impact
Gland Pharma Grants 5.9 Lakh Stock Options to 124 Employees
Gland Pharma has granted 5,90,249 stock options to 124 employees under its ESOP 2025 scheme. Options are priced at ₹1,461.15 and ₹1. Vesting occurs over three years starting September 13, 2027, with exercise within two years of vesting.
Read the summary - Low impact
Gland Pharma Board Comments on ₹1.4 Lakh Fines for Director Age Rule Breach
Gland Pharma's Board addressed fines of ₹70,000 each from NSE and BSE for a 3-4 day breach of director age regulations. Shareholder approval was obtained on July 18, 2026, for Mr. William Keller's appointment. The company has paid the total ₹1.4 Lakh fine and enhanced compliance processes.
Read the summary - Low impact
Gland Pharma Schedules Analyst/Institutional Investor Meetings from Sep 16-25, 2026
Gland Pharma Limited will conduct analyst and institutional investor meetings from September 16 to September 25, 2026. This includes one-on-one meetings with East Bridge Capital, IIFL Capital, and Antique Broking, as well as a group meeting with Nomura.
Read the summary - Low impact
Gland Pharma Sets Analyst Meet with DSP Mutual Fund on Sep 11, 2026
Gland Pharma Limited will hold a one-on-one investor meeting with DSP Mutual Fund on September 11, 2026. The schedule is subject to change.
Read the summary - Low impact
Gland Pharma Schedules Investor Meeting with Kotak Mutual Fund on Sep 9
Gland Pharma Limited will hold a one-on-one meeting with Kotak Mutual Fund on September 09, 2026. This is part of the company's investor engagement activities.
Read the summary - Medium impact
Gland Pharma's Visakhapatnam facility clears USFDA inspection with zero observations
Gland Pharma's Visakhapatnam facility passed a USFDA GMP inspection from August 24 to September 1, 2026. The inspection concluded with zero Form 483 observations, signaling strong regulatory compliance.
Read the summary - Low impact
Gland Pharma Schedules Investor Meetings from Sep 3 to Sep 24, 2026
Gland Pharma Limited will hold a series of Analyst and Institutional Investor Meetings from September 3 to September 24, 2026. The meetings include one-on-one sessions with Carnelian Capital, First Ray Capital, WCM Investment, and LIC MF, as well as group meetings and participation in the BofA Securities 2026 Asia Pacific Conference.
Read the summary - Medium impact
Gland Pharma: AGM Voting Results and Dividend Approval Confirmed
Gland Pharma's 48th AGM on August 25, 2026, approved financial statements and a final dividend. Reappointments of Directors Mr. Wenjie Zhang and Ms. Wei Huang were also confirmed. All five resolutions passed with requisite majority.
Read the summary - High impact
Gland Pharma Holds 48th AGM, Executive Chairman Reviews FY26 Performance
Gland Pharma's 48th AGM was held on August 25, 2026. The company reported FY26 consolidated revenue of ₹64,307 million, up 14% YoY. EBITDA was ₹16,295 million (25% margin), up 28% YoY. PAT was ₹10,273 million, up 47% YoY. Cenexi revenues grew 25% to ₹18,693 million.
Read the summary - Low impact
Gland Pharma Schedules Investor Meetings on Aug 26 & 27, 2026
Gland Pharma Limited will hold one-on-one meetings with Nomura on August 26, 2026, and with HDFC MF on August 27, 2026. These meetings are for analysts and institutional investors.
Read the summary - High impact
Gland Pharma Q1 FY27: Revenue Up 20% to ₹18,003 Million, PAT Grows 47%
Gland Pharma's Q1 FY27 revenue rose 20% YoY to ₹18,003 million. PAT grew 47% to ₹3,170 million. CDMO and B2B segments each contributed 50% of revenue. The company signed a strategic manufacturing deal with potential USD 90-100 million revenue from 2029.
Read the summary - Medium impact
Gland Pharma Appoints Deepak Sapra as New CEO Effective November 16, 2026
Gland Pharma Limited announced the appointment of Mr. Deepak Sapra as its new Chief Executive Officer (CEO). Mr. Sapra will join the company on November 16, 2026. He has 27 years of executive experience, including over 23 years in pharmaceuticals, and previously served as CEO of API and Services at Dr. Reddy’s Laboratories.
Read the summary - Low impact
Gland Pharma Publishes Q1FY27 Unaudited Financial Results
Gland Pharma Limited announced its Unaudited Financial Results for Q1FY27, ending June 30, 2026. The results were approved by the Board on August 10, 2026, and are available on the company and stock exchange websites.
Read the summary - Low impact
Gland Pharma Uploads Q1 FY27 Earnings Call Recording
Gland Pharma released the audio recording of its Q1 FY27 earnings call held on August 10, 2026. The recording is available on the company website, accessible via a provided weblink.
Read the summary - Low impact
Gland Pharma Schedules Analyst/Institutional Investor Meetings from Aug 13-20, 2026
Gland Pharma will conduct analyst and institutional investor meetings from August 13 to August 20, 2026. Key meetings include UTI MF on August 13 and Ashmore on August 20, with participation in the Motilal Oswal Investor Conference on August 17.
Read the summary - High impact
Gland Pharma Q1FY27 Results: Revenue up 20% to ₹18,003 Cr, PAT grows 47%
Gland Pharma reported Q1FY27 revenue of ₹18,003 crore, up 20% YoY. PAT grew 47% to ₹3,170 crore. CDMO revenue increased 20% and B2B revenue rose 19%. The company launched 4 molecules in the USA and filed 3 ANDAs. Strategic collaborations and in-licensing agreements were also highlighted.
Read the summary - High impact
Gland Pharma Q1FY27 Revenue Up 20% to ₹18,003 Cr, PAT Jumps 47%
Gland Pharma reported Q1 FY27 results with revenue at ₹18,003 crore, up 20% YoY. PAT surged 47% to ₹3,170 crore. Both CDMO and B2B segments grew robustly. The company launched 4 new molecules in the USA and anticipates significant revenue from a new CDMO partnership starting in 2029.
Read the summary - Medium impact
Gland Pharma Approves Q1 FY27 Unaudited Financial Results
Gland Pharma Limited's Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026. The results include both standalone and consolidated figures. A press release and investor presentation were also released.
Read the summary - High impact
Gland Pharma inks Strategic CDMO Deal with Global Pharma Co.
Gland Pharma has signed a strategic Manufacturing and Supply Agreement with a global pharmaceutical company for sterile injectables. The deal includes technology transfer, manufacturing, and supply, with revenue expected from 2029. The annualized revenue potential is USD 90-100 million (approx. ₹750-₹830 crore) for 55 SKUs.
Read the summary - High impact
Gland Pharma inks CDMO deal with global co. for $90-100M revenue potential
Gland Pharma has signed a strategic Manufacturing and Supply Agreement (MSA) with a global pharmaceutical company for sterile injectables. The deal offers long-term business visibility, with revenue generation expected from CY2029. The partnership covers 55 SKUs across three sites, with an estimated annualized revenue potential of USD 90-100 million (₹750-830 crore).
Read the summary - Medium impact
Gland Pharma & Neuland Labs Ink Strategic CDMO Partnership for Sterile API Manufacturing
Gland Pharma and Neuland Laboratories announced a long-term strategic CDMO partnership for sterile API manufacturing. Gland Pharma will establish a new sterile manufacturing suite at its Visakhapatnam facility, adding 1400 kg of annual capacity. The collaboration leverages complementary strengths to enhance global supply of sterile APIs for microparticle depot products.
Read the summary - Medium impact
Gland Pharma Announces 48th AGM, E-voting, and Final Dividend Details
Gland Pharma's 48th AGM is on August 25, 2026. Remote e-voting is from August 22-24, 2026. A final dividend of ₹20 per share is recommended. The record date for the dividend is August 11, 2026.
Read the summary - Low impact
Gland Pharma Announces 48th AGM on Aug 25, 2026, and FY26 Dividend of ₹20/share
Gland Pharma will hold its 48th AGM on August 25, 2026. A final dividend of ₹20 per share for FY2025-26 will be paid, with a record date of August 11, 2026. Shareholders are reminded to update KYC details.
Read the summary - Low impact
Gland Pharma submits Business Responsibility and Sustainability Report for FY25-26
Gland Pharma Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for FY25-26, complying with SEBI regulations. The report details ESG performance, operational data, and adherence to ISO and WHO GMP standards. It is available on the company's website.
Read the summary - Medium impact
Gland Pharma Announces 48th AGM on Aug 25, 2026, Proposes ₹20 Final Dividend
Gland Pharma will hold its 48th AGM on August 25, 2026, via VC/OAVM. The company proposes a final dividend of ₹20 per equity share for FY26. Key agenda items include adopting financial statements and reappointing directors Mr. Wenjie Zhang and Ms. Wei Huang. E-voting is open from Aug 22-24, 2026.
Read the summary - Low impact
Gland Pharma Allots 6,979 Equity Shares on ESOP Exercise
Gland Pharma Limited allotted 6,979 equity shares on July 30, 2026, to 8 employees upon exercise of stock options under its ESOP Scheme 2025. This increased the company's paid-up share capital to ₹16,49,66,661/-, comprising 16,49,66,661 equity shares.
Read the summary - Low impact
Gland Pharma Grants 16,790 Stock Options to 3 Employees Under ESOP 2025
Gland Pharma has approved the grant of 16,790 stock options to 3 employees under its ESOP 2025 scheme. The grant includes 11,081 options at ₹1258.50 and 5,709 options at ₹1. Vesting begins July 30, 2027, over three years.
Read the summary - Medium impact
Gland Pharma Secures USFDA Approval for Sugammadex Injection Vials
Gland Pharma received USFDA approval for Sugammadex Injection in 200 mg/2 mL and 500 mg/5 mL vials. The product is a generic equivalent to BRIDION® Injection. It has been launched in the US, where the drug had sales of approximately USD 1.6 billion (₹13,300 crore) for the twelve months ending April 2026.
Read the summary - Low impact
Gland Pharma Announces 48th AGM on August 25, 2026, via VC/OAVM
Gland Pharma Limited will hold its 48th Annual General Meeting on August 25, 2026, at 11:00 AM IST. The meeting will be conducted virtually via Video Conferencing/Other Audio-Visual Means. Financial statements for FY2025-26 will be shared electronically.
Read the summary - Low impact
Gland Pharma to Host Q1 FY27 Earnings Call on August 10, 2026
Gland Pharma Limited will host its Q1 FY27 earnings conference call on August 10, 2026, at 18:30 IST. The management will discuss financial performance and business updates for the quarter ended June 30, 2026. Transcript and audio will be available on the company website.
Read the summary - Medium impact
Gland Pharma Reappoints Udo Vetter, Appoints William Keller as Independent Directors
Gland Pharma shareholders approved the re-appointment of Mr. Udo Vetter as Independent Director for a second five-year term from July 21, 2026, to July 20, 2031. Additionally, Mr. William Keller was appointed as an Independent Director for five years, effective June 15, 2026, to June 14, 2031.
Read the summary - Medium impact
Gland Pharma shareholders approve director reappointments and remuneration
Gland Pharma Limited's shareholders have approved the reappointment of Mr. Udo Jahannes Vetter and the appointment of Mr. William Robert Keller as Independent Directors. Remuneration and commission on profits for these directors, along with a revision for Mr. Essaji Goolam Vahanvati, were also approved via postal ballot.
Read the summary - Low impact
Gland Pharma Receives IGST Demand Order; Files Appeal
Gland Pharma received an IGST demand and penalty order for ₹3.52 crore for FY21-22 from Customs Authority. The company disputes the demand and will file an appeal. Gland Pharma expects no material financial impact.
Read the summary - Low impact
Gland Pharma: Certificate Under SEBI (Depositories and Participants) Regulations, 2018
Gland Pharma Limited submitted a confirmation certificate for Q1 FY27 as per SEBI regulations. The certificate from MUFG Intime India confirms dematerialization and registration of securities. This is a routine compliance filing.
Read the summary - Low impact
Gland Pharma Closes Trading Window from June 27 for Q1 FY27 Results
Gland Pharma's trading window will be closed from June 27, 2026. It will reopen 48 hours after the declaration of the Unaudited Financial Results for the quarter ending June 30, 2026. The date for the board meeting to approve these results will be announced later.
Read the summary - Low impact
Gland Pharma Schedules Analyst/Institutional Investor Meeting on June 25, 2026
Gland Pharma Limited will hold an analyst and institutional investor meeting on June 25, 2026. The one-on-one meeting will be with Ambit PMS, arranged by B&K / 360One. The schedule is subject to change.
Read the summary - Low impact
Gland Pharma Ltd: Newspaper ad for dispatch of Postal Ballot Notice & e-voting
Gland Pharma Limited announced the dispatch of its Notice of Postal Ballot and e-voting information. Members will vote on reappointing and appointing independent directors and revising remuneration. E-voting is open from June 19 to July 18, 2026. Results will be declared by July 20, 2026.
Read the summary - Medium impact
Gland Pharma Seeks Shareholder Approval for Director Reappointments and Remuneration
Gland Pharma is seeking shareholder approval via postal ballot for director reappointments and remuneration. Key proposals include reappointing Udo Jahannes Vetter and appointing William Robert Keller as Independent Directors. Shareholders will also vote on commission-based remuneration for these directors, capped at ₹5.5 million annually. The e-voting period is June 19 to July 18, 2026.
Read the summary - Low impact
Gland Pharma Schedules Analyst/Institutional Investor Meeting on June 22, 2026
Gland Pharma Limited will hold a one-on-one meeting with SiMPL PMS on June 22, 2026. The meeting is arranged by Kotak Securities. The schedule is subject to change.
Read the summary - Low impact
Gland Pharma Schedules Investor Meetings for June 19 and June 25
Gland Pharma Limited will conduct one-on-one meetings with ICICI Prudential AMC and Jefferies on June 19, 2026. The company will also meet with Valuequest Investment Advisors on June 25, 2026. The schedule is subject to change.
Read the summary - Low impact
Gland Pharma Independent Director Satyanarayana Murthy Chavali Resigns
Gland Pharma's Independent Director, Mr. Satyanarayana Murthy Chavali, resigned effective June 15, 2026. The resignation is due to a potential conflict of interest as his other company plans to enter a similar business segment. He confirmed no other material reasons for his departure.
Read the summary - Medium impact
Gland Pharma Board Appoints New Director, Reappoints Another, Accepts Resignation
Gland Pharma's Board reappointed Udo Jahannes Vetter as Independent Director (July 21, 2026 - July 20, 2031) and appointed William Robert Keller as Additional Director (effective June 15, 2026). Satyanarayana Murthy Chavali resigned as Independent Director (effective June 15, 2026) due to a potential conflict of interest. Essaji Goolam Vahanvati appointed to subsidiary board.
Read the summary - Medium impact
Gland Pharma Board Approves Director Reappointments, Appointments, and Resignation
Gland Pharma's Board re-appointed Udo Jahannes Vetter as an Independent Director for a second five-year term from July 21, 2026. William Robert Keller was appointed as an Additional Director (Non-Executive - Independent) effective June 15, 2026. Satyanarayana Murthy Chavali resigned as Independent Director due to a potential conflict of interest.
Read the summary - Low impact
Gland Pharma Publishes Newspaper Notice for Member Communication
Gland Pharma Limited published a notice on June 10, 2026, in English and Telugu newspapers as per SEBI regulations. Shareholders are urged to update their email addresses for electronic communication of statutory information. This applies to physical shareholdings via the RTA and dematerialized holdings via Depository Participants.
Read the summary - Low impact
Gland Pharma Schedules Analyst/Institutional Investor Meetings from June 9-11, 2026
Gland Pharma Limited will hold analyst and institutional investor meetings from June 9 to June 11, 2026. Meetings include one-on-one sessions with Haitong Securities, ICICI Securities, Midas Research, and Sohum Asset. The schedule is subject to change.
Read the summary - Low impact
Gland Pharma Allots 2,03,259 Equity Shares on Employee Stock Option Exercise
Gland Pharma allotted 2,03,259 equity shares on June 02, 2026, to 77 employees upon exercise of stock options. This increases the company's paid-up share capital to Rs. 16.50 crore. The shares were issued under the Gland Pharma Employee Stock Options Scheme, 2025.
Read the summary - Low impact
Gland Pharma Schedules Analyst/Institutional Investor Meetings for June 4, 2026
Gland Pharma Limited has scheduled analyst and institutional investor meetings for June 04, 2026. These include a group meeting arranged by BofA and a one-on-one meeting with Emkay Global. The schedule is subject to change.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio